Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
Purpose
This phase II trial studies how well talazoparib works in treating patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer that has come back after previous treatment. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions
- ATM Gene Mutation
- ATR Gene Mutation
- BARD1 Gene Mutation
- BRCA1 Gene Mutation
- BRCA2 Gene Mutation
- BRIP1 Gene Mutation
- CHEK1 Gene Mutation
- CHEK2 Gene Mutation
- FANCA Gene Mutation
- FANCC Gene Mutation
- FANCD2 Gene Mutation
- FANCF Gene Mutation
- FANCM Gene Mutation
- NBN Gene Mutation
- PALB2 Gene Mutation
- RAD51 Gene Mutation
- RAD51B Gene Mutation
- RAD54L Gene Mutation
- Recurrent Squamous Cell Lung Carcinoma
- RPA1 Gene Mutation
- Stage IV Squamous Cell Lung Carcinoma AJCC v7
Eligibility
- Eligible Ages
- All ages
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Criteria
Inclusion Criteria:
- Patients must meet all SCREENING/PRE-SCREENING and SUB-STUDY REGISTRATION COMMON
ELIGIBILITY CRITERIA as specified in S1400: Phase II/III Biomarker-Driven Master
Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
- Patients must be assigned to S1400G; S1400G biomarker eligibility defined as
homologous recombination repair deficiency (HRRD) positive is as follows
- Biomarker-positive group
- HRRD by FMI
- Homologous recombination repair deficiency by Foundation Medicine Inc.,
criteria
- Alteration type
- Truncating mutation, frameshift deletions, indels missense and nonsense
mutations predicted to have functional consequence in any of the specified
genes
- Eligible alteration
- Mutation in any one of the following critical HRR pathway genes: ATM, ATR,
BARD1, BRCA1, BRCA2, BRIP1, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCF,
FANCM, NBN (NBS1), PALB2, RAD51, RAD51B (RAD51L1), RAD54L, RPA1
- Patients must not have had prior exposure to any agent with a PARP inhibitor (e.g.,
veliparib, olaparib, rucaparib, niraparib, talazoparib [BMN 673]) as its primary
pharmacology
- Patients must have achieved stable disease, a partial response, or a complete response
at their first disease assessment after initiating first-line platinum-based
chemotherapy; patients determined to have progressed (in the opinion of the treating
physician) at their first disease assessment are not eligible
- Patients may not have any impairment of gastrointestinal function or gastrointestinal
disease that may significantly alter the absorption of talazoparib (BMN 673) (e.g.,
ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome,
small bowel resection, or active peptic ulcer disease); patients must not have active
small or large intestine inflammation such as Crohn's disease or ulcerative colitis
(within 12 months of sub-study registration)
- Patients must be able to take oral medications; patients must be able to swallow
capsules whole without crushing or altering them in any way
- Patients must not be taking, nor plan to take while on protocol treatment strong
P-glycoprotein (P-gp) inhibitors, P-gp inducers, or breast cancer resistance protein
(BCRP) inhibitors; the language ?P-gp or BCRP inhibitors or inducers? is reworded to
?strong P-gp inhibitors, P-gp inducers, or BCRP inhibitors? for consistency with the
investigator brochure
- Patients must agree to have blood specimens submitted for pharmacokinetic analysis
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Treatment (talazoparib) |
Patients receive talazoparib PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. |
|
More Details
- Status
- Completed
- Sponsor
- SWOG Cancer Research Network
Study Contact
Detailed Description
PRIMARY OBJECTIVES: I. To evaluate the overall response rate (ORR) (confirmed and unconfirmed, complete and partial) with talazoparib (BMN 673) in HRRD Medivation (MDVN)-positive patients. SECONDARY OBJECTIVES: I. To evaluate investigator assessed progression-free survival (IA-PFS) and overall survival (OS) associated with therapy in HRRD MDVN-positive patients. II. To evaluate ORR, IA-PFS, and OS in HRRD Foundation Medicine, Inc. (FMI)-positive patients. III. To evaluate ORR in HRRD MDVN-negative/HRRD FMI-positive patients. IV. To evaluate the frequency and severity of toxicities associated with talazoparib (BMN 673) in HRRD FMI-positive patients. TERTIARY OBJECTIVES: I. To assess if the homologous recombination deficiency (HRD) score is associated with clinical outcomes (response, PFS, OS) in HRRD FMI-positive patients treated with talazoparib (BMN 673). II. To assess if the level of PARP protein expression determined by immunohistochemistry is associated with clinical outcomes (response, PFS, OS) in HRRD FMI-positive patients treated with talazoparib (BMN 673). III. To characterize pharmacokinetic properties of talazoparib (BMN 673). OUTLINE: Patients receive talazoparib orally (PO) once daily (QD) on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 1 year, every 6 months for 2 years, and at the end of year 3.